Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.53 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.47 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.43 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.42 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.42 |
| ▸ | RBP4 | P02753 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4325183 | 0.91 | HSD11B1 (0.46) | HSD11B1SLC6A7PDK1PDK2PDK3 | |
| SCHEMBL4419799 | 0.89 | ALDH1A1 (0.48) | TRPA1 | |
| SCHEMBL4333478 | 0.88 | ALDH1A1 (0.46) | HSD11B1TRPA1 | |
| SCHEMBL4326369 | 0.87 | MALT1 (0.48) | HSD11B1TRPA1TRPV1RBP4 | |
| SCHEMBL4326377 | 0.87 | SLC6A7 (0.58) | HSD11B1SLC6A7 | |
| SCHEMBL4324240 | 0.86 | KIT (0.49) | — | |
| SCHEMBL4318039 | 0.86 | MEN1 (0.56) | SLC6A7 | |
| SCHEMBL4321993 | 0.86 | HSD11B1 (0.49) | HSD11B1SLC6A7RBP4 | |
| SCHEMBL4321006 | 0.84 | RBP4 (0.52) | RBP4 | |
| SCHEMBL4312067 | 0.83 | HSD11B1 (0.46) | HSD11B1SLC6A7RBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | WYETH (US) | 2009-12-31 | — | — | US | claimed |
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | WYETH (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | GRM5, GRIK5, GRM1 | HSD11B1 3183/4885TRPA1 1855/4885TRPV1 634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.